(Q33366804)

26 July 2017

title

Tuberculous pleural effusion: 6-month therapy with isoniazid and rifampin (English)

1 reference

26 July 2017

1 reference

0 references

A. K. Dutt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1596014

12 October 2022

D. Moers

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1596014

12 October 2022

W. W. Stead

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1596014

12 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1596014

12 October 2022

publication date

1 June 1992

1 reference

The American Review of Respiratory Disease

26 July 2017

published in

1 reference

26 July 2017

volume

145

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

1429-1432

1 reference

Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients.

26 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1164%2FAJRCCM%2F145.6.1429

Short-course antituberculous chemotherapy for pulmonary and pleural disease: 5 years' experience in clinical practice

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1164%2FAJRCCM%2F145.6.1429

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F145.6.1429

State of the art. The pleura

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1164%2FAJRCCM%2F145.6.1429

10.1164/AJRCCM/145.6.1429

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference